Page last updated: 2024-11-08

dimethylphenylpiperazinium iodide and Chronic Disease

dimethylphenylpiperazinium iodide has been researched along with Chronic Disease in 1 studies

Dimethylphenylpiperazinium Iodide: A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
De Man, JG1
Moreels, TG1
De Winter, BY1
Bogers, JJ1
Van Marck, EA1
Herman, AG1
Pelckmans, PA1

Other Studies

1 other study available for dimethylphenylpiperazinium iodide and Chronic Disease

ArticleYear
Disturbance of the prejunctional modulation of cholinergic neurotransmission during chronic granulomatous inflammation of the mouse ileum.
    British journal of pharmacology, 2001, Volume: 133, Issue:5

    Topics: Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists;

2001